Previous 10 | Next 10 |
DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Con...
- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose - DUBLIN, Ireland, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused ...
Summary Avadel's LUMRYZ in treatment of cataplexy in adults with narcolepsy received tentative FDA approval, temporarily blocked by a patent owned by Jazz Pharmaceuticals. The situation creates a David vs. Goliath match-up of great importance for both companies. Jazz is taking the f...
Summary Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy. We rate AVDL a buy now with the overhang removed, with far more clarity on the route to full FDA approval...
- Delisting of REMS Patent sets path to potentially accelerate final approval by FDA DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Ireland-based biopharma Avadel Pharmaceuticals ( NASDAQ: AVDL ) added ~26% on Friday to reach the highest level since March, as Needham noted that recent comments made by the Federal Trade Commission (FTC) could lead to imminent FDA approval for its lead asset Lumryz. FD...
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare C...
Avadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Conference Call November 09, 2022, 08:00 AM ET Company Participants Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Offic...
Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q3 GAAP EPS of -$0.33 misses by $0.07 . Cash, cash equivalents and marketable securities were $106.5 million as of September 30, 2022. Also, as of September 30, 2022, the Company had $26.4 million of convertibl...
LUMRYZ™ granted tentative approval on July 18, confirming its safety profile and clinical efficacy Final approval decision of LUMRYZ expected by June 2023; advancing strategy to potentially accelerate final approval Commercial launch planned for no later t...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...